CT/NG Testing Market worth $2.69 billion by 2030, growing at a CAGR of 7.41% - Exclusive Report by 360iResearch

The "CT/NG Testing Market by Product (Assays & Kits, Instruments & Analyzers), Testing Type (Lab Tests, PoC Tests), Technology, End User - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.

The Global CT/NG Testing Market to grow from USD 1.63 billion in 2023 to USD 2.69 billion by 2030, at a CAGR of 7.41%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/ct-ng-testing?utm_source=openpr&utm_medium=referral&utm_campaign=sample

The CT/NG testing is primarily focused on the accurate diagnosis, management, and prevention of sexually transmitted infections (STIs), including Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The increasing prevalence of chlamydia and gonorrhea infections worldwide and rising awareness about the risks associated with untreated STIs also fuel the need for timely identification and appropriate treatment options. Technological diagnostics advancements offer opportunities for improving accuracy in detecting CT/NG infections while minimizing turnaround times. The development of POC test kits, allowing rapid results without any need for laboratory infrastructure, has gained immense popularity since it enables faster clinical decision-making. However, high costs associated with advanced diagnostic tests coupled with variations in government regulations across different countries concerning diagnostic tests limit product penetration worldwide. Nevertheless, the growing adoption of molecular diagnostics methods and government-led initiatives to promote STI screening programs to facilitate early detection and prevention of complications associated with untreated infections contribute positively to the growth of the CT/NG testing market.

A growing demand for point-of-care diagnostics for sexually transmitted infections (STIs), increasing prevalence of chlamydia and gonorrhea infections, and government initiatives targeting early detection and treatment have expanded the need for CT/NG testing. In the EU countries, a rising focus on STI prevention programs to address the public health challenges investments for improving diagnostic methods through research contribute to the CT/NG testing market. The Middle East & Africa region exhibits significant potential for CT/NG testing growth due to increased government efforts towards improving STI awareness and access to healthcare services. With a large population and growing awareness around sexual health following education campaigns by the Asia-Pacific government, the region presents a lucrative CT/NG testing market.

Market Segmentation & Coverage:

This research report categorizes the CT/NG Testing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Assays & Kits and Instruments & Analyzers. The Assays & Kits is projected to witness significant market share during forecast period.

Based on Testing Type, market is studied across Lab Tests and PoC Tests. The Lab Tests is projected to witness significant market share during forecast period.

Based on Technology, market is studied across Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology, and Polymerase Chain Reaction. The Immunodiagnostics is projected to witness significant market share during forecast period.

Based on End User, market is studied across Clinical Laboratories and Hospitals & Clinics. The Clinical Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 36.83% in 2023, followed by Europe, Middle East & Africa.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/ct-ng-testing?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the CT/NG Testing Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the CT/NG Testing Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the CT/NG Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Binx Health, Inc., Bio-Rad Laboratories, Inc., Bioneer Corporation, Danaher Corporation, ELITech Group SAS, F. Hoffmann-La Roche Ltd., Geneproof A.S., Genetic Signatures Ltd., Goffin Molecular Technologies B.V., Hologic, Inc., Meridian Bioscience Inc., Microbiologics, Inc., Molbio Diagnostics Pvt. Ltd., Operon S.A., PerkinElmer Inc., QIAGEN N.V., Sansure Biotech Inc., Seegene, Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tianlong Technology Co., Ltd., Vircell S.L., and Visby Medical, Inc..

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. CT/NG Testing Market, by Product
7. CT/NG Testing Market, by Testing Type
8. CT/NG Testing Market, by Technology
9. CT/NG Testing Market, by End User
10. Americas CT/NG Testing Market
11. Asia-Pacific CT/NG Testing Market
12. Europe, Middle East & Africa CT/NG Testing Market
13. Competitive Landscape
14. Competitive Portfolio

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the CT/NG Testing Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the CT/NG Testing Market?
3. What is the competitive strategic window for opportunities in the CT/NG Testing Market?
4. What are the technology trends and regulatory frameworks in the CT/NG Testing Market?
5. What is the market share of the leading vendors in the CT/NG Testing Market?
6. What modes and strategic moves are considered suitable for entering the CT/NG Testing Market?

Read More @ https://www.360iresearch.com/library/intelligence/ct-ng-testing?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.